Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical...
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical...
MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences...
Initial patients expected in June 2026 SAN DIEGO, CA / ACCESS Newswire / June 4, 2026 / Modular Medical, Inc....
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan...
Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities MIAMI,...
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as...
State-Level Reform, Growing Public Acceptance, and Expanding Market Capitalizations Signal Potential Long-Term Industry Opportunity LAS VEGAS, NV / ACCESS Newswire...
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and...
AHZANTIVE® (aflibercept) is an EMA-approved biosimilar to Eylea® (aflibercept) with demonstrated similarity in efficacy, safety and immunogenicity to the reference product The launch expands Teva’s biosimilars portfolio and presence in ophthalmology, in line with the Company’s...
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and...
Peer-reviewed randomized controlled trial of 427 adults found that after completing Noom’s 16-week program, members continued losing weight for the...
First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending...
First Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off +...
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class...
WASHINGTON, June 04, 2026 (GLOBE NEWSWIRE) -- The Melanoma Research Alliance (MRA), the world's leading nonprofit funder of melanoma research,...
With the coming HT Scan capture app, HoloTwin 2.0 forms an end-to-end platform for creating digital twins of buildings and...
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports...
Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitutionCompetitive Generic Therapy approval provides 180 days of...
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...